ASCO 2022 Conference Coverage


 

ASCO 2022 on KEYNOTE-651: Pembrolizumab + mFOLFOX7/FOLFIRI for mCRC: Long-Term Follow-Up of Cohorts B and D

2,345 views
June 9, 2022
Comments 0
Login to view comments. Click here to Login